Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Enhanced Proton Conductivity Promoted by Structural Transition in a 2D Interwoven Metal-Organic Framework.
Cryst Growth Des
January 2025
Department of Chemistry, University of Manchester, Manchester M13 9PL, U.K.
We report enhanced proton conductivity promoted by a structural phase transition of MFM-504(Cu)-DMF to MFM-504(Cu)-MeOH and to MFM-504(Cu)-OH via ligand substitution upon exposure to MeOH and HO vapors, respectively. MFM-504(Cu)-DMF can be synthesized by the solvothermal reaction of Cu(NO)·3HO and the flexible zwitterionic ligand, imidazolium-1,3-bis(methylenedicarboxylate) (imidc), to afford a unique layered interwoven network structure. MFM-504(Cu)-OH shows a proton conductivity of 5.
View Article and Find Full Text PDFLabor Roulette: The Probability of Achieving Spontaneous Labor in Normal-Risk Nulliparous Patients.
Am J Obstet Gynecol MFM
January 2025
Rotunda Hospital, Dublin, Ireland; Department of Obstetrics and Gynaecology, Royal College of Surgeons in Ireland, (RCSI), University of Medicine and Health Sciences, Dublin, Ireland.
Association of omega-3 fatty acid supplementation with recurrent preterm birth by obesity status.
Am J Obstet Gynecol MFM
January 2025
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Electronic address:
Reply to Letter to the Editor regarding "The Preeclampsia and Hypertension Target Treatment Study: a multicenter prospective study to evaluate the effectiveness of the antihypertensive therapy based on maternal hemodynamic findings.
Am J Obstet Gynecol MFM
January 2025
Department of Women and Child Health, Women Health Area, Catholic University of Sacred Heart, Fondazione Policlinico Agostino Gemelli, IRCCS, Rome, Italy.
Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe.
Thromb Haemost
January 2025
Guy's and St Thomas' NHS Foundation Trust, King's College London, United Kingdom.
Background: The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.
Methods: ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!